WhichPepsPeptides. Without the hype.

Glutathione

Endogenous tripeptide antioxidant

Redox biologydeficiency states
Generic peptide vial illustrationGlutathione
Entity typePeptide
Evidence reviewed2026-09-18
Canonical recordGLUTATHIONE
Page updated2026-09-20
Evidence profileHuman evidence exists but is route/indication specific and mixed
Human evidenceClinical evidence
Regulatory statusProduct/jurisdiction-specific
Choose your depthStart simple, then open the evidence or technical detail only if you need it.
Quick answerPlain languageEvidenceOutcomes and studiesStudiesPrimary recordsTechnicalMechanism, route and identifiers

In plain English

30-second evidence answer

What does the evidence mean in simple terms?

Glutathione has been studied in people, but results depend heavily on the condition, route and formulation being tested. That evidence does not establish a broad “detox”, anti-ageing or wellness effect from injectable glutathione.

Still uncertain: Broad detox, anti-ageing, wellness or disease-prevention benefits from unspecified injectable products.

New to terms such as “preclinical”, “randomized” or “investigational”? Use the plain-English glossary →

What does the evidence mean in simple terms? table
What is it?Endogenous tripeptide antioxidant
Entity typePeptide
Research focusRedox biology, deficiency states, antioxidant research
Human evidenceHuman studies are route- and outcome-specific. Oral trials include both increased measured glutathione stores and null oxidative-stress findings; a small randomized IV Parkinson trial did not show a significant efficacy difference versus placebo.
Regulatory statusGlutathione itself is endogenous; therapeutic approval and compounding status are product/jurisdiction specific.
Main limitationsBroad detox, anti-ageing or wellness benefit from unspecified injectable glutathione.
SafetySafety is route/indication specific; compounded injectable use should not be inferred from oral or endogenous biology.
Evidence reviewed2026-09-18
i
Human studies are route- and outcome-specific. Oral trials include both increased measured glutathione stores and null oxidative-stress findings; a small randomized IV Parkinson trial did not show a significant efficacy difference versus placebo.
Outcome-level evidence

Evidence is not one score.

Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.

How to read this →

Increasing measured glutathione body stores

Human evidence
Randomized placebo-controlled human evidence

Context: Healthy adults taking oral glutathione

Finding: Oral glutathione can alter measured glutathione stores under some study conditions.

Uncertainty / evidence gap: This does not prove broad detoxification, anti-ageing or disease-prevention outcomes.

Verified 2026-09-18Primary source ↗

Systemic oxidative-stress biomarker improvement

Human evidence
Randomized placebo-controlled human evidence

Context: Healthy adults taking oral glutathione

Finding: A controlled human trial produced a null result despite biological plausibility.

Counter-evidence / null result: Primary biomarker findings were negative.

Verified 2026-09-18Primary source ↗

IV glutathione for Parkinson motor symptoms

Human evidence
Small randomized double-blind pilot

Context: People with Parkinson's disease

Finding: Small IV disease-specific exposure provides direct human route evidence.

Counter-evidence / null result: Preliminary efficacy endpoint was negative.

Verified 2026-09-18Primary source ↗
Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.

Evidence synthesis

  • ✓Oral glutathione can alter measured glutathione stores under some study conditions.
  • ✓A controlled human trial produced a null result despite biological plausibility.
  • ✓Small IV disease-specific exposure provides direct human route evidence.

Important limitations

  • !Biomarker endpoint in healthy adults; route-specific.
  • !Short trial; healthy population.
  • !N=21; disease-specific; not a wellness or skin-lightening trial.

Selected study & evidence records

Effects of oral glutathione supplementation on systemic oxidative stress biomarkers

2011 · Randomized, double-blind, placebo-controlled clinical trial · n=40

No significant between-group changes in measured oxidative-stress biomarkers or glutathione indices.

Study detail → Primary source ↗

Randomized controlled trial of oral glutathione supplementation on body stores of glutathione

2015 · Randomized, double-blind, placebo-controlled trial · n=54

Glutathione stores increased in several compartments, generally in a dose- and time-dependent pattern.

Study detail → Primary source ↗

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

2009 · Randomized, double-blind, placebo-controlled pilot trial · n=21

No statistically significant difference in UPDRS change versus placebo.

Study detail → Primary source ↗

Safety and unknowns

Safety is route/indication specific; compounded injectable use should not be inferred from oral or endogenous biology.

Technical details

Mechanism / biologyMajor intracellular redox buffer and cofactor involved in oxidative-stress defence.
Route / formulation boundaryDo not generalize oral/topical/inhaled findings to injections.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published oral human trial regimen; Published longer-term oral trial regimens. Open descriptive regimen evidence →
Identifiers & alternate namesGSH

Source depth & provenance

WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.

3structured study records
3outcome records
7linked source records

How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.

Show supporting and discovery sources

Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.